August press release website.jpg

SIME Dx Announces New Design for Lung Maturity Diagnostic Device

LONDON, August 15, 2018 /PRNewswire/ -- Device fully automates neonatal Lung Maturity Test (LMT), representing a major milestone achievement and putting LMT on track for final clinical validation and commercialisation.  

SIME Dx, a digital molecular medicine company focused on the development and commercialisation of point-of-care (POC) diagnostics, today announced a new device design that fully automates the company's novel neonatal Lung Maturity Test (LMT). LMT, the first application on the patented Digital Molecular Diagnostics (DMDx) platform, has been clinically proven to predict Respiratory Distress Syndrome (RDS) with high accuracy. RDS is the leading cause of morbidity and mortality in premature babies, and can only be prevented with early diagnosis and targeted treatment.


SIME Dx selected by Disrupt 100 as one of 100 Global businesses 'with the most potential to influence, change, or create new global markets.'

The report tracks the world’s most disruptive businesses, compiled and curated by the world’s leading entrepreneurs, investors and business people. Each Disrupt 100 venture was sourced from over 5M global startups and corporate ventures, has been scored against a specific criteria measuring the potential it has to affect an existing market or geography, introduce new customers into an existing market and/or creating a new market with significant customer demand. The ventures were then judged by global brands including Google, Uber, Oracle, Silicon Valley Bank and Virgin StartUp, tech accelerators Microsoft Ventures, Accelerated Digital Ventures and Whitespace Ventures and entrepreneurs Emma Sinclair, Tom Goodwin and Bill Liao. We are honoured to be listed alongside such a range of innovative and disruptive companies! A sure sign that we are slowly stepping into the spotlight.

EU press release.jpg

Project Delivers Strong Clinical Data, IP and Prototype of Rapid Neonatal Lung Maturity Test

LONDON, Jan. 11, 2018 /PRNewswire/ -- SIME Dx, a digital molecular medicine company developing point-of-care diagnostics, has announced the completion of a 2 year EU Horizon 2020 project. The project has significantly accelerated company progress, culminating in the publication of clinical data validating a rapid Lung Maturity Test (LMT), an engineering prototype and new IP. The €2.86 million funding enabled SIME Dx to overcome technical challenges, and prepared the company for further clinical trials, regulatory approval, commercialisation and expansion into China.  

Microsoft news story.jpg

A British Company has Created a Simple Test to Help Premature Babies

In December of 2016, Microsoft UK published a feature article about SIME Dx's bedside test, and the potential it had to "improve the lives of millions of premature babies ." 

The feature was amongst the best-read articles of the year and, therefore, was highlighted as one of the 10 biggest UK stories of 2017.

Business wire image website.jpg

Data for a Rapid Lung Maturity Test
Published in ACTA

Recently Published European Consensus Guidelines Highlight the Need for a Bedside Test

LONDON--(BUSINESS WIRE)--SIME Dx, a digital molecular medicine company developing point-of-care diagnostics, announced data validating the efficacy of a lung maturity test (LMT) in identifying infants at risk of respiratory distress syndrome (RDS) who could benefit from early surfactant treatment. 


Name *